PlantForm is proud to be advancing biologics innovation with CDMO services using our cost-effective, plant-based vivoXPRESS manufacturing platform.
Learn more: https://t.co/HohAfOXJOj
#cdmo#biologics#biopharma#BIO2022#LimitlessTogether
This work beautifully integrates the power of proteomics and metabolomics with the promise of plants for drug discovery. Very excited to see it published! @PlantFormCorp@CNPN_org
We'll be at the International Society for Plant Molecular Farming (ISPMF) Conference May 6-8! 🌿
Thank you to #CanExport Innovation @tcs_sdc for supporting our work to forge new partnerships that bring Canadian biotech innovation to the world!
#export#ISPMF2024
Read this @BioProcessIntl article about our work leveraging plant-based protein-expression systems for #biodefense applications:
https://t.co/AbcJ1SkXgT
Press release: AntoXa Corporation and SwiftPharma Sign Exclusive Collaboration Agreement to Support the Development and Commercialization of a Plant-Made Antibody Against Ricin Exposure
Full release: https://t.co/la4fSy4k17
Ricin is in the news again: this lethal substance, found naturally in castor beans, is 6,000 times deadlier than cyanide and a tiny amount can cause death within 36 hours.
https://t.co/5rgdNdg3Qj
The PhD9 antibody drug candidate developed by DRDC prevents ricin from penetrating cells. The process has received United States Patent No. 11,447,789.
PRESS RELEASE: PlantForm and @UBC researcher Dr. Joerg Bohlmann receive @glyconet_nce funds to develop novel, plant-based treatment option for Type-2 diabetes
Read the full release here: https://t.co/K4J1RXV0gl
PRESS RELEASE: PlantForm Corporation and Bio-Manguinhos/Fiocruz sign new agreement to develop a #biosimilar pembrolizumab cancer drug and up to 5 future products for the Brazilian and other world markets.
Full release: https://t.co/45h0EKESBA
In our latest blog post, we examine the trends shaping the #biosimilars industry & discuss the impact of innovative techs on biosimilar development. Learn how @PlantFormCorp's vivoXPRESS® & Alto Digital #SPR can streamline biosimilar production.
Link: https://t.co/2rBQgBZmKF
AntoXa, a wholly-owned subsidiary of PlantForm Corporation, has an exclusive license from DRDC to develop and produce the PhD9 monoclonal antibody treatment in plants for sale in markets worldwide.
The patent is for a plant-based manufacturing process to produce an antibody for treatment of ricin exposure, an outcome of R&D by AntoXa Corporation under contract with Defence Research and Development Canada (DRDC), an Agency of the Canadian Department of National Defence.